TREATMENT OUTCOMES OF UTERINE CARCINOMA: A SINGLE INSTITUTION RETROSPECTIVE STUDY

Authors

  • Bakhan Mahmood Karim Radiation Oncology, Zhianawa Cancer Center, Kurdistan Region, Iraq.
  • Chro Najmaddin Fattah College of Medicine, University of Sulaimani, Kurdistan Region, Iraq.
  • Jalil Salih Ali Radiation Oncology, Zhianawa Cancer Center, Kurdistan Region, Iraq.

DOI:

https://doi.org/10.17656/jsmc.10422

Keywords:

Uterine cancer, radiotherapy, survival outcomes

Abstract

Background
Endometrial cancer has a lifetime risk of 2.6% for women living in industrialized countries and it is the most prevalent kind of cancer diagnosed in those regions. In terms of gynecologic cancer-related deaths, it ranks after ovarian and cervical cancer as the third most common cause.


Objectives
To evaluate endometrial cancer patients’ long-term treatment outcomes, including disease-free survival and overall survival, as well as to pinpoint independent predictive markers.


Materials and Methods
At the Zhianawa Cancer Center, a retrospective analysis was conducted. All patients who had been referred for radiation therapy between March 2009 and January 2019 were included in the research, except those who had distant metastases. In the end, 89 patients were included. Using the Kaplan-Meier technique, overall survival and disease-free survival were calculated, and the significance of the variations across curves was evaluated using the log-rank test.


Results
All patients underwent surgery, 96.6% received adjuvant radiotherapy, and 42.7% received concomitant chemotherapy. The 5-year and 10-year disease-free survivals were 62.9% and 56.2%, and the overall 5-year and 10-year survivals were 74.2% and 66.3% respectively. The statistically significant variables impacting disease-free survival were lymphovascular invasion and marginal status, and the only statistically significant prognostic variable affecting overall survival was the FIGO stage.


Conclusion
In this analysis, we concluded that uterine cancer has a good prognosis, and its outcome was influenced by stage, lymphovascular space invasion, and surgical marginal status.

References

Moxley KM, McMeekin DS. Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents. Oncologist.2010; 1: 1026–1033. DOI: https://doi.org/10.1634/theoncologist.2010-0087

Oaknin A, Rodríguez-Freixinós V, Díaz de Corcuera I, Rivera F, del Campo J. SEOM guidelines for endometrial cancer. Clinical and Translational Oncology. 2012;14(7):512-515. DOI: https://doi.org/10.1007/s12094-012-0833-z

Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2013; 24: 33-38. DOI: https://doi.org/10.1093/annonc/mdt353

Boll D, Verhoeven R, van der Aa M, Pauwels P, Karim-Kos H, Coebergh J et al. Incidence and Survival Trends of Uncommon Corpus Uteri Malignancies in the Netherlands, 1989–2008. International Journal of Gynecological Cancer. 2012;22(4):599-606. DOI: https://doi.org/10.1097/IGC.0b013e318244cedc

Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1): 10–17. DOI: https://doi.org/10.1016/0090-8258(83)90111-7

Silverberg S, Elder D, Kurman R. Tumors of the uterine corpus and gestational trophoblastic disease. Washington, D.C.: Armed Forces Institute of Pathology; 1996.

Abeler VM, Vergote IB, Kjorstad KE, Trope CG. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer 1996; 78(8): 1740–1747. DOI: https://doi.org/10.1002/(SICI)1097-0142(19961015)78:8<1740::AID-CNCR14>3.0.CO;2-Y

Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982; 6(2): 93–108. DOI: https://doi.org/10.1097/00000478-198203000-00002

McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumours) are metaplastic carcinomas. Int J Gynecol Cancer. 2002; 12(6): 687–690. DOI: https://doi.org/10.1136/ijgc-00009577-200211000-00001

Albrektsen G, Heuch I, Wik E, Salvesen HB. Prognostic impact of parity in 493 uterine sarcoma patients. Int J Gynecol Cancer.2009; 19(6): 1062–1067. DOI: https://doi.org/10.1111/IGC.0b013e3181aaa950

Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin . 2017; 67(1): 7-30. DOI: https://doi.org/10.3322/caac.21387

Ueda S, Kapp D, Cheung M, Shin J, Osann K, Husain A et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. American Journal of Obstetrics and Gynecology. 2008;198(2): 218.e1-218.e6. DOI: https://doi.org/10.1016/j.ajog.2007.08.075

Chan J, Sherman A, Kapp D, Zhang R, Osann K, Maxwell L et al. Influence of Gynecologic Oncologists on the Survival of Patients with Endometrial Cancer. Journal of Clinical Oncology. 2011;29(7):832-838. DOI: https://doi.org/10.1200/JCO.2010.31.2124

Benedetti Panici P, Basile S, Salerno M, Di Donato V, Marchetti C, Perniola G et al. Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma. American Journal of Obstetrics and Gynecology. 2014;210(4): 363.e1-363.e10. DOI: https://doi.org/10.1016/j.ajog.2013.12.025

Doll K, Tseng J, Denslow S, Fader A, Gehrig P. High-grade endometrial cancer: Revisiting the impact of tumour size and location on outcomes. Gynecologic Oncology. 2014;132(1):44-49. DOI: https://doi.org/10.1016/j.ygyno.2013.10.023

Creasman WT. New gynecologic cancer staging. Obstet Gynecol. 1990; 75(2): 287–8.

Todo Y, Sakuragi N. Systematic lymphadenectomy in endometrial cancer. J Obstet Gynaecol Res. 2013; 39(2): 471– 477. DOI: https://doi.org/10.1111/j.1447-0756.2012.02062.x

Creasman W, Odicino F, Maisonneuve P, Quinn M, Beller U, Benedet J et al. Carcinoma of the Corpus Uteri. International Journal of Gynecology & Obstetrics. 2006;95: S105-S143. DOI: https://doi.org/10.1016/S0020-7292(06)60031-3

American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: Management of endometrial cancer. Obstet Gynecol. 2005; 106: 413– 425. DOI: https://doi.org/10.1097/00006250-200508000-00050

Creutzberg C, van Putten W, Koper P, Lybeert M, Jobsen J, Wárlám-Rodenhuis C et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: a multicentre randomised trial. The Lancet. 2000;355(9213):1404-1411. DOI: https://doi.org/10.1016/S0140-6736(00)02139-5

Keys H, Roberts J, Brunetto V, Zaino R, Spirtos N, Bloss J et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology. 2004;92(3):744-751. DOI: https://doi.org/10.1016/j.ygyno.2003.11.048

Nout R, Smit V, Putter H, Jürgenliemk-Schulz I, Jobsen J, Lutgens L et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. The Lancet. 2010;375(9717):816-823. DOI: https://doi.org/10.1016/S0140-6736(09)62163-2

Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG 2007; 114(11): 1313-1320. DOI: https://doi.org/10.1111/j.1471-0528.2007.01332.x

Onsrud M, Cvancarova M, Hellebust T, Tropé C, Kristensen G, Lindemann K. Long-Term Outcomes After Pelvic Radiation for Early-stage Endometrial Cancer. Journal of Clinical Oncology. 2013;31(31):3951-3956. DOI: https://doi.org/10.1200/JCO.2013.48.8023

Johnson N, Bryant A, Miles T, Hogberg T, Cornes P. Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev 2011: CD003175. DOI: https://doi.org/10.1002/14651858.CD003175.pub2

Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer—results from two randomised studies. Eur J Cancer. 2010; 46(13): 2422–31. DOI: https://doi.org/10.1016/j.ejca.2010.06.002

Hirai M, Hirono M, Oosaki T, Hayashi Y, Yoshihara T, Matsuzaki O. Prognostic factors relating to survival in uterine endometrioid carcinoma. Int J Gynaecol Obstet. 1999;66 (2): 155–162. DOI: https://doi.org/10.1016/S0020-7292(99)00067-3

Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynaecological system: an analysis of 1973–1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. 1994;10 (1):31–46. DOI: https://doi.org/10.1002/ssu.2980100107

Gal D, Recio FO, Zamurovic D, Tancer ML. Lymphvascular space involvement} a prognostic indicator in endometrial adenocarcinoma. Gynecol Oncol. 1991;42(2): 142-145. DOI: https://doi.org/10.1016/0090-8258(91)90334-2

Semaan A, Ali-Fehmi R, Munkarah A, Bandyopadhyay S, Morris R, Rizk S et al. Clinical/pathologic features and patient outcome in early-onset endometrial carcinoma: A population-based analysis and an institutional perspective from the Detroit metropolitan area, Michigan. Gynecologic Oncology. 2012;124(2):265-269. DOI: https://doi.org/10.1016/j.ygyno.2011.09.027

Wen Q, Shao Z, Yang Z. Concomitant paclitaxel plus carboplatin and radiotherapy for high-risk or advanced endometrial cancer. Int J Gynecol Cancer. 2013;23(4):685-9. DOI: https://doi.org/10.1097/IGC.0b013e3182808232

Published

2023-09-21

How to Cite

1.
Karim B, Fattah C, Ali J. TREATMENT OUTCOMES OF UTERINE CARCINOMA: A SINGLE INSTITUTION RETROSPECTIVE STUDY. JSMC [Internet]. 2023 Sep. 21 [cited 2024 Jun. 19];13(3):8. Available from: https://jsmc.univsul.edu.iq/index.php/jsmc/article/view/jsmc-10422

Similar Articles

1-10 of 105

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)